About Vera Therapeutics
Vera Therapeutics is a company based in San Francisco (United States) founded in 2016 by Marshall Fordyce. Vera Therapeutics has raised $196.58 million across 5 funding rounds from investors including Fidelity Investments, ARE and Kleiner Perkins. The company has 112 employees as of December 31, 2024. Vera Therapeutics offers products and services including Atacicept. Vera Therapeutics operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter San Francisco, United States
- Employees 112 as on 31 Dec, 2024
- Founders Marshall Fordyce
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vera Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$152.15 M (USD)-58.5as on Dec 31, 2024
-
EBITDA
-$165 M (USD)-58.85as on Dec 31, 2024
-
Total Equity Funding
$196.58 M (USD)
in 5 rounds
-
Latest Funding Round
$80 M (USD), Series C
Jan 19, 2021
-
Investors
Fidelity Investments
& 8 more
-
Employee Count
112
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Vera Therapeutics
Vera Therapeutics is a publicly listed company on the NASDAQ with ticker symbol VERA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Vera Therapeutics
Vera Therapeutics offers a comprehensive portfolio of products and services, including Atacicept.
Drug for treating IgA Nephropathy in clinical trials
People of Vera Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
33 people
Software Development Team
6 people
Operations Team
5 people
Finance and Accounting
4 people
Product Management Team
4 people
Sales and Marketing
3 people
Program Team
1 people
Data Analysis and Operations Team
1 people
Unlock access to complete
Funding Insights of Vera Therapeutics
Vera Therapeutics has successfully raised a total of $196.58M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vera Therapeutics
Vera Therapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, ARE and Kleiner Perkins.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
Private equity firm focused on life science sector
|
Locked | Locked | Locked | |
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked |
Investor details for Vera Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vera Therapeutics
Investment portfolio details for Vera Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vera Therapeutics
Detailed financials for Vera Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vera Therapeutics Comparisons
Peer comparison for Vera Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vera Therapeutics
Vera Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
Detailed competitors of Vera Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vera Therapeutics
Complete news archive for Vera Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vera Therapeutics
Vera Therapeutics was founded in 2016.
Vera Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Marshall Fordyce is the current CEO of Vera Therapeutics. They have also founded this company.
Vera Therapeutics is a funded company, having raised a total of $196.58M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Vera Therapeutics is 112.
Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases. The company has an atacicept novel biologic drug that is a human recombinant fusion protein that helps in treating IgA nephropathy which is a rare autoimmune disease. It contains a soluble TACI receptor that binds to the cytokines BLyS and APRIL to promote B-cell survival and autoantibody production for the treatment of autoimmune diseases.
Vera Therapeutics's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
Vera Therapeutics offers Atacicept.
Yes, Vera Therapeutics is publicly traded on NASDAQ under the ticker symbol VERA.
Vera Therapeutics has 9 investors. Key investors include Fidelity Investments, ARE, Kleiner Perkins, HHS, and Abingworth.
The ticker symbol of Vera Therapeutics is VERA on NASDAQ.